Company news

Cardiff Oncology, Inc. news in 2021

Cardiff Oncology, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

December 9, 2021

Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 2, 2021

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative

November 17, 2021

Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences

November 8, 2021

Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates

November 3, 2021

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

September 7, 2021

Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021

August 24, 2021

Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

August 4, 2021

Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

July 11, 2021

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021

July 5, 2021

Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes

June 27, 2021

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

June 9, 2021

Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

June 7, 2021

Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights

May 5, 2021

Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC

April 11, 2021

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021

March 9, 2021

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights

February 24, 2021

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

January 25, 2021

Decks in 2021